<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Strunk C</submitter><funding>NIMHD NIH HHS</funding><pagination>102612</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8643307</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>92</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Sickle cell disease (SCD) is characterized by frequent, unpredictable pain episodes and other vaso-occlusive crises (VOCs) leading to significant healthcare utilization. VOC frequency is often an endpoint in clinical trials investigating novel therapies for this devastating disease.&lt;h4>Procedure&lt;/h4>The Consortium for the Advancement of Sickle Cell Research (CASiRe) is an international collaboration investigating clinical severity in SCD using a validated questionnaire and medical chart review standardized across four countries (United States, United Kingdom, Italy and Ghana).&lt;h4>Results&lt;/h4>This study, focused on pain crisis incidence and healthcare utilization, included 868 patients, equally represented according to age and gender. HgbSS was the most common genotype. P</pubmed_abstract><journal>Blood cells, molecules &amp; diseases</journal><pubmed_title>Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.</pubmed_title><pmcid>PMC8643307</pmcid><funding_grant_id>T37 MD001425</funding_grant_id><pubmed_authors>Rao S</pubmed_authors><pubmed_authors>Inusa B</pubmed_authors><pubmed_authors>Wilson S</pubmed_authors><pubmed_authors>Kim E</pubmed_authors><pubmed_authors>Ekem I</pubmed_authors><pubmed_authors>Rivers A</pubmed_authors><pubmed_authors>Farooq F</pubmed_authors><pubmed_authors>Boatemaa GD</pubmed_authors><pubmed_authors>Tartaglione I</pubmed_authors><pubmed_authors>Andemariam B</pubmed_authors><pubmed_authors>Colombatti R</pubmed_authors><pubmed_authors>Urbonya R</pubmed_authors><pubmed_authors>Haile H</pubmed_authors><pubmed_authors>Manwani D</pubmed_authors><pubmed_authors>Piccone CM</pubmed_authors><pubmed_authors>Boruchov D</pubmed_authors><pubmed_authors>Perrotta S</pubmed_authors><pubmed_authors>Segbefia C</pubmed_authors><pubmed_authors>Asare EV</pubmed_authors><pubmed_authors>Strunk C</pubmed_authors><pubmed_authors>Smith A</pubmed_authors><pubmed_authors>Antwi-Boasiako C</pubmed_authors><pubmed_authors>Campbell AD</pubmed_authors><pubmed_authors>Sey F</pubmed_authors><pubmed_authors>Zempsky W</pubmed_authors><pubmed_authors>Sainati L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.</name><description>&lt;h4>Background&lt;/h4>Sickle cell disease (SCD) is characterized by frequent, unpredictable pain episodes and other vaso-occlusive crises (VOCs) leading to significant healthcare utilization. VOC frequency is often an endpoint in clinical trials investigating novel therapies for this devastating disease.&lt;h4>Procedure&lt;/h4>The Consortium for the Advancement of Sickle Cell Research (CASiRe) is an international collaboration investigating clinical severity in SCD using a validated questionnaire and medical chart review standardized across four countries (United States, United Kingdom, Italy and Ghana).&lt;h4>Results&lt;/h4>This study, focused on pain crisis incidence and healthcare utilization, included 868 patients, equally represented according to age and gender. HgbSS was the most common genotype. P</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-04-25T20:54:27.526Z</modification><creation>2025-04-06T08:32:57.304Z</creation></dates><accession>S-EPMC8643307</accession><cross_references><pubmed>34564050</pubmed><doi>10.1016/j.bcmd.2021.102612</doi></cross_references></HashMap>